Wegovy Jabs: Separating Fact from the Noise

The biggest myth: Wegovy jabs are a quick cosmetic fix

The most persistent misconception about Wegovy jabs is that they are a shortcut, something to take for a few weeks before a holiday or to shift a stubborn few pounds. The MHRA has stated plainly that GLP-1 medicines are not assessed for quick or cosmetic weight loss. These are clinically regulated treatments developed for people whose weight is affecting their health, studied over periods of a year or more, and prescribed within a framework that includes diet, activity and regular clinical review.

The STEP 1 trial (published in the New England Journal of Medicine) followed adults with obesity over 68 weeks. Participants using semaglutide 2.4mg alongside lifestyle changes achieved an average body-weight reduction of around 15%. That figure comes from sustained treatment, not a brief course. The more recently approved 7.2mg dose reported roughly 20.7% average weight loss over 72 weeks in clinical trials, narrowing the gap with tirzepatide. These are averages from controlled trials; individual results differ, and a prescriber will never guarantee a specific outcome for any patient.

Framing this as a lifestyle product also ignores the clinical gatekeeping involved. You cannot walk into a pharmacy and leave with a Wegovy pen. A prescriber must review your health history, confirm your BMI meets the licensed threshold, check for contraindications and satisfy themselves that treatment is appropriate. That step is not optional, it is the law.

What actually happens when you inject, and what arrives

Wegovy comes as a pre-filled, single-use pen. Each pen contains one weekly dose, injected into the fatty tissue of the abdomen, thigh or upper arm, sites should be rotated to avoid irritation at any one spot. The injection itself uses a fine needle; most people describe the sensation as mild and brief once they are used to the technique.

When treatment is dispensed through a regulated online pharmacy, what you receive is a discreet, plain box via tracked courier, at nume, that means a DPD notification on your phone and next-working-day delivery once your prescription has been clinically approved. The pen is stored in the fridge (2–8°C) until the night before or morning of your injection day; you take it out to reach room temperature before use. Exact storage windows are detailed in the Patient Information Leaflet that comes with every pen, always follow that, not a general article.

The single-dose Wegovy jab at 7.2mg, approved by the MHRA on 14 April 2026, uses an auto-dosing mechanism with a built-in covered needle that locks after use, making the process simpler for people who find pen management daunting. That approval applies to adults with a BMI of 30 or above only; the starting dose remains 0.25mg regardless of which maintenance dose you eventually reach.

Who the Wegovy jab is (and is not) licensed for in the UK

The licensed eligibility criteria are set by the MHRA and reflected in NICE's appraisal of semaglutide for weight management (TA875). In straightforward terms: adults with a BMI of 30 or above qualify on BMI alone; those with a BMI between 27 and 29.9 qualify if they have at least one weight-related condition such as high blood pressure, pre-diabetes, obstructive sleep apnoea or high cholesterol. A 2.5 kg/m² lower threshold applies for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance.

There are groups for whom Wegovy is not recommended. Pregnancy, breastfeeding and trying to conceive all fall outside the licensed use. The treatment is not licensed for anyone under 18. People with a personal or family history of medullary thyroid carcinoma or MEN2, or those with a history of pancreatitis, require careful prescriber discussion before any GLP-1 medicine is considered. These are not bureaucratic hurdles, they reflect genuine clinical risk.

It is also worth being precise about what Wegovy is not. Ozempic contains the same active ingredient (semaglutide) but holds a UK licence for type 2 diabetes management, not weight loss. Rybelsus is oral semaglutide licensed for diabetes. If you have been reading about semaglutide-based weight-loss injections under various names, Wegovy is the one licensed for weight management in the UK. The semaglutide overview page covers those distinctions in more detail.

What ongoing Wegovy treatment actually involves

Starting Wegovy jabs is the beginning of a structured clinical process, not a one-off event. The dose titration schedule (moving from 0.25mg through 0.5mg, 1.0mg, 1.7mg and eventually 2.4mg (or beyond, for those moving to 7.2mg)) is designed to allow your digestive system to adjust. Rushing that process is not something a responsible prescriber will do. The NICE recommendation under TA875 also specifies that if fewer than 5% of body weight has been lost after six months on the maintenance dose, continuing treatment should be reviewed.

Side effects peak for most people around dose increases, particularly the early steps. Nausea, loose stools and fatigue are common; they are rarely reasons to stop treatment, but your prescriber needs to know about them. Pancreatitis is a less common but more serious risk: the MHRA highlighted acute pancreatitis as a known concern in its January 2026 Drug Safety Update for GLP-1 medicines. Severe, persistent abdominal pain that radiates to the back (with or without vomiting) warrants urgent medical attention, not waiting for your next check-in. Any suspected side effect can be reported at the MHRA's Yellow Card scheme.

The weight-loss jabs Wegovy guide goes further on managing treatment month to month. If you are weighing up whether this type of injection-based treatment suits you compared to other approaches, our page on fat jabs and how Wegovy fits into that category is worth reading alongside the weight-loss treatments overview. People who want a broader picture of how semaglutide jabs work across different doses and formulations will find that page a helpful companion before booking a consultation. For those ready to find out whether they meet the clinical criteria, the consultation is free and reviewed the same day by a real GPhC-registered prescriber, not software. Check your eligibility here.